Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lallemantia royleana polysaccharide is a high-molecular-weight water-soluble polysaccharide obtained from the seeds of the Lallemantia royleana plant, known for its traditional medicinal use in Iran and surrounding regions. The polysaccharide is primarily composed of arabinose, galactose, and rhamnose, with minor components including xylose and glucose. It has demonstrated hypocholesterolemic (lipid-lowering), antioxidant, and antimicrobial activities in preclinical models. The mechanism of action is believed to involve antioxidant properties and modification of lipid metabolism, though exact molecular targets remain undetermined. Studies indicate potential as a functional food component for cardiovascular and metabolic disease prevention, but it is not a registered pharmaceutical. Research is preclinical, focusing on animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lallemantia royleana polysaccharide.